Vetter Pharma
Vetter Pharma, officially known as Vetter Pharma-Fertigung GmbH & Co. KG, is a leading global provider of aseptic filling and packaging services for the pharmaceutical and biotechnology industries. Headquartered in Ravensburg, Germany, the company operates extensively across Europe, North America, and Asia, catering to a diverse clientele. Founded in 1950, Vetter Pharma has achieved significant milestones, including the development of innovative delivery systems and a commitment to high-quality standards. The company specialises in prefilled syringes, vials, and cartridges, distinguished by their precision and reliability. Vetter's strong market position is underscored by its reputation for excellence and a robust portfolio of services that support drug development and commercialisation. With a focus on customer-centric solutions, Vetter Pharma continues to be a trusted partner in the evolving landscape of healthcare.
DitchCarbon Score
How does Vetter Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Vetter Pharma's score of 47 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Vetter Pharma's reported carbon emissions
In 2023, Vetter Pharma reported total carbon emissions of approximately 17,852,000 kg CO2e, with Scope 1 emissions accounting for about 17,852,000 kg CO2e and Scope 3 emissions at approximately 3,613,000 kg CO2e. Notably, there were no reported Scope 2 emissions. This represents a reduction from 2022, where emissions were about 18,000,000 kg CO2e for Scope 1 and approximately 2,861,000 kg CO2e for Scope 3. Vetter Pharma has set ambitious climate commitments, aiming for a significant reduction in emissions. The company targets a 58.8% reduction in Scope 1 and 2 emissions by 2030, using 2021 as the base year. Additionally, they are committed to an annual reduction of 4.2% in CO2 emissions from the same base year. Furthermore, Vetter Pharma plans to reduce energy consumption in terms of gross value added by 10% by 2029, compared to 2019 levels. Long-term, Vetter Pharma aims to achieve net zero emissions by 2050, indicating a comprehensive approach to sustainability and climate responsibility within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 19,683,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | - |
| Scope 3 | 97,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Vetter Pharma is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
